Other languages Calithera Biosciences, Inc.

Equities

CALA

US13089P5070

Market Closed - OTC Markets Other stock markets 02:55:29 2024-04-18 pm EDT			5-day change	1st Jan Change
0.025 ^USD	-37.38%		-49.80%	-16.33%

2023	Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s Disease	CI
2023	North American Morning Briefing : Stock Futures -2-	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s Disease	23-06-14
Calithera Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31
Calithera Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30
Top Premarket Decliners	23-01-25
Calithera Biosciences Shares Set to be Suspended From Nasdaq on Feb. 2; Stock Declines Premarket	23-01-25
Top Midday Decliners	23-01-09
Calithera Biosciences to Proceed With Liquidation and Dissolution of Company	23-01-09
Calithera Biosciences, Inc. Announces Departure of Susan M. Molineaux as Chief Executive Officer	23-01-09
Calithera Biosciences, Inc. Announces Executive Departures	23-01-09
Antengene Corporation Limited Enters into Assignment Agreement with Calithera Biosciences, Inc. to Acquire All Outstanding Rights of ATG-037	23-01-04
Calithera Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14
Calithera Biosciences Receives FDA's Fast Track Designation for Lung Cancer Drug Candidate; Shares Climb	22-10-03
Calithera Biosciences, Inc. Receives U.S. Food & Drug Administration Fast Track Designation for Sapanisertib for the Treatment of NRF2-Mutated Squamous Lung Cancer	22-10-03
Calithera Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15
Calithera Biosciences, Inc. Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences	22-07-13
Calithera Biosciences Enrolls First Patient in Phase 2 Lung Cancer Trial; Shares Rise After Hours	22-07-06
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory Nrf2-Mutated Squamous Non-Small Cell Lung Cancer	22-07-06
Calithera Biosciences Starts Enrollment in Phase 2 Trial of Mivavotinib in Diffuse Large B-cell Lymphoma Subtype	22-06-23
Calithera Biosciences, Inc. Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB Diffuse Large B-Cell Lymphoma	22-06-23
Calithera Biosciences to Effect 1-for-20 Reverse Stock Split to Regain Compliance	22-06-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Calithera Biosciences, Inc.

Equities

CALA

US13089P5070

Other languages

Filters